scholarly journals Dual-strand tumor suppressor miR-193b-3p and -5p inhibit malignant phenotypes of lung cancer by suppressing their common targets

2019 ◽  
Vol 39 (7) ◽  
Author(s):  
Kyung Hee Choi ◽  
Chang Hoon Shin ◽  
Woo Joo Lee ◽  
Haein Ji ◽  
Hyeon Ho Kim

Abstract Emerging studies suggest that microRNAs (miRNAs) play multiple roles in cancer malignancy, including proliferation and acquisition of metastatic potential. Differentially expressed miRNAs responsible for the malignancy of lung cancer were searched by miRNA microarray using a previously established brain metastatic lung cancer model. Twenty-five miRNAs were down-regulated in brain metastatic lung cancer cells. Among those, miR-193b-3p and -5p were chosen for further studies. Their function in metastatic potential and proliferation was examined using Transwell invasion, wound healing, and colony forming assays. The underlying mechanism of tumor-suppressor miR-193b-3p and -5p was explored using reverse transcriptase quantitative polymerase chain reaction (RT-qPCR), Western blot, Argonaute 2-RNA immunoprecipitation (Ago2-RIP), and reporter assays. Both strands of miR-193b were down-regulated in brain metastatic lung cancer cells and in tissues from lung cancer patients. Overexpression of miR-193b-3p and -5p inhibited invasive and migratory activities and diminished clonogenic ability. Conversely, inhibition of miR-193b-3p or -5p increased the metastatic potential and colony forming ability. Cyclin D1 (CCND1), Ajuba LIM Protein (AJUBA), and heart development protein with EGF like domains 1 (HEG1) were identified as common target genes of miR-193b-3p and -5p. A reporter assay and an Ago2-RIP experiment showed that both miRNAs directly bind to the 3′ untranslated region (3′UTR) of the target mRNA. Knockdown of target gene reduced the proliferative and metastatic potential of primary and metastatic lung cancer cells. Our results demonstrate miR-193b is a dual-strand tumor suppressor and a novel therapeutic target for lung cancer.

Oncotarget ◽  
2015 ◽  
Vol 6 (26) ◽  
pp. 22905-22917 ◽  
Author(s):  
Xiaopan Cai ◽  
Jian Luo ◽  
Xinghai Yang ◽  
Huayun Deng ◽  
Jishen Zhang ◽  
...  

2018 ◽  
Vol 143 (1) ◽  
pp. 88-99 ◽  
Author(s):  
Giovanni Sette ◽  
Valentina Salvati ◽  
Ilenia Giordani ◽  
Emanuela Pilozzi ◽  
Denise Quacquarini ◽  
...  

2016 ◽  
Vol 8 (6) ◽  
pp. 1217-1226 ◽  
Author(s):  
Jiacong You ◽  
Rui Chang ◽  
Bin Liu ◽  
Lingling Zu ◽  
Qinghua Zhou

Author(s):  
Adriana Rojas Moreno ◽  
Alejandra Cañas Arboleda ◽  
Angelica Herreño ◽  
Maria Jose Fernandez ◽  
Juan Andres Mejia ◽  
...  

Cell Reports ◽  
2021 ◽  
Vol 37 (4) ◽  
pp. 109880
Author(s):  
Jillian Hattaway Luttman ◽  
Jacob P. Hoj ◽  
Kevin H. Lin ◽  
Jiaxing Lin ◽  
Jing Jin Gu ◽  
...  

2021 ◽  
Vol 3 (Supplement_3) ◽  
pp. iii2-iii2
Author(s):  
Ann Marie Pendergast ◽  
Jacob Hoj ◽  
Benjamin Mayro

Abstract Brain metastases are the most common intracranial tumors in adults and are associated with increased patient morbidity and mortality. Limited therapeutic options are currently available for the treatment of brain metastasis. We have identified an actionable signaling pathway utilized by metastatic tumor cells whereby the transcriptional regulator Heat Shock Factor 1 (HSF1) drives a transcriptional program, divergent from its canonical role as the master regulator of the heat shock response, leading to enhanced expression of a subset of E2F transcription factor family gene targets. We showed that HSF1 is required for survival and outgrowth by metastatic lung cancer cells in the brain parenchyma. Unexpectedly, we identified the ABL2 tyrosine kinase as an upstream regulator of HSF1 protein expression, and showed that the Src-homology 3 (SH3) domain of ABL2 directly interacts with HSF1 protein at a non-canonical, proline-independent SH3 interaction motif. Importantly, knockdown of ABL2 impairs expression of HSF1 protein and HSF1-E2F transcriptional gene targets. Notably, we found that pharmacologic inhibition of the ABL kinases using selective ABL allosteric inhibitors, but not ATP-competitive inhibitors, ablates the physical interaction between ABL2 and HSF1, leading to markedly decreased expression of HSF1, E2F1 and E2F8 proteins in brain-metastatic lung cancer cells, and depletion of HSF1-E2F transcriptional targets. These findings highlight potential differences affecting intra- and inter-molecular protein-protein interactions induced by allosteric versus ATP-competitive kinase inhibitors that have important therapeutic implications. Importantly, the targetable nature of the ABL2-HSF1-E2F signaling network identifies ABL allosteric inhibitors as a potentially effective therapy for the treatment of metastatic lung cancers characterized by high expression of HSF1.


2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e19065-e19065 ◽  
Author(s):  
C. Lu ◽  
D. J. Stewart ◽  
L. Ji ◽  
R. Ramesh ◽  
G. Jayachandran ◽  
...  

e19065 Background: The tumor suppressor gene FUS1 is frequently inactivated early in lung cancer development. FUS1 mediates apoptosis in cancer cells but not normal cells through its interaction with Apaf1. DOTAP:cholesterol nanoparticles encapsulating a FUS1 expression plasmid showed selective uptake by cancer cells and activity in mouse xenograft metastatic lung cancer models. Methods: Patients with recurrent/metastatic lung cancer previously treated with platinum-based chemotherapy were treated with escalating doses of intravenous DOTAP:cholesterol FUS1 nanoparticles. Nanoparticle-DNA complexes were manufactured in GMP facilities to meet specifications of OD400, size, appearance, and transfection efficiency. Results: Patients have received doses ranging from 0.01–0.09 mg/kg at 3 week intervals. To date 23 patients have been entered on study at 6 dose levels, with 21 patients currently evaluable for the primary endpoint of cycle 1 toxicity. 70% of subjects had received 2 or more prior chemotherapy regimens. Among 4 patients treated without premedications, all 4 developed grade 2 or higher fevers within 24 hours of treatment. Among the 17 patients premedicated with dexamethasone and diphenhydramine, 4 developed grade 1 fever. There have been no other grade 2 or higher drug-related toxicities. Four patients received only one dose because of rapidly progressing disease at a site requiring local treatment. Fifteen patients received two or more doses and are evaluable for response, with 4 patients achieving stable disease and 11 patients progressing. Median survival time for all patients is 10.3 months. A maximum tolerated dose (MTD) has not been reached. Pre and 24 hour posttreatment tumor biopsies were obtained from 4 patients. A quantitative real time reverse transcriptase PCR (RT-PCR) analysis using a plasmid FUS1 sequence-specific probe have been performed on 3 paired-samples blinded to time of biopsy. A high level of plasmid FUS1 expression was detected in all 3 posttreatment samples but not in three pretreatment samples and negative controls by RT-PCR. Conclusions: DOTAP:cholesterol FUS1 nanoparticles can be safely administered intravenously in lung cancer patients with demonstrable gene expression in posttreatement tumor biopsies. [Table: see text]


2014 ◽  
Vol 37 (6) ◽  
pp. 457-466 ◽  
Author(s):  
Hophil Min ◽  
Dohyun Han ◽  
Yikwon Kim ◽  
Jee Yeon Cho ◽  
Jonghwa Jin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document